Skip to content

Posts tagged ‘ESMO 2011’

2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer News

September 26th, 2011


It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride.

Stockholm 2011 Multidisciplinary Cancer Congress 300x168 2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer NewsThe phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) in Stockholm this past weekend.

Pieter Droppert has two posts on Biotech Strategy Blog from the Congress about the potentially “practice changing” Alpharadin prostate cancer data:

He also took the opportunity to interview Dr Chris Parker, Consultant Clinical Oncologist at The Royal Marsden Hospital, who presented the ALSYMPCA phase 3 trial results, and a video blog post will follow.

Stockholm Cancer Congress 2011 Social Media 300x169 2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer NewsLive conference twitter board at #EMCC2011 

Sally Church on Pharma Strategy Blog aggregated all the tweets from the 2011 ESMO ECCO congress in Stockholm.  With only a few people tweeting, the twitter stream doesn’t report all the news, but does give a flavor of an excellent cancer meeting with a good balance of science and clinical data.

It’s an exciting time for prostate cancer patients and physicians with multiple new treatment options on the horizon. However, the fast moving and dynamic prostate cancer market is likely to present Pharma/Biotech marketing strategy professionals with opportunities and challenges. Alpharadin is on the fast track to FDA approval in 2012.

Follow coverage of 2011 Stockholm Cancer Congress #EMCC2011

September 22nd, 2011


Stockholm Waterfront 2011 300x169 Follow coverage of 2011 Stockholm Cancer Congress  #EMCC2011The 2011 Stockholm Multidisciplinary Cancer Congress (more commonly known as ECCO 2011 or ESMO 2011) is underway in Stockholm, Sweden.

Pieter Droppert (@3NT) will be writing on Biotech Strategy Blog from the meeting and in particular the new data on prostate cancer that will be presented, in particular the phase 3 Alpharadin ALSYMPCA trial data that is a late breaking abstract.

Sally Church (@MaverickNY) will be covering several sessions live on Twitter. On Pharma Strategy Blog, Sally is aggregating the live tweets from the meeting (#EMCC2011). If you are unable to be in Stockholm for the meeting this weekend, you can follow the action remotely. As Sally would say, “check it out.”

Conference Coverage: the week in review

September 9th, 2011


Now that summer is officially over, the fall pharma/biotech conference season has started. You can find out details of the conferences Icarus Consultants will be attending by checking out our conference schedule.

If you are interested in our meeting coverage services or a conference report, please contact us.

Boston Prudential Center 169x300 Conference Coverage: the week in reviewThis week, we followed two conferences remotely through Twitter.  On Biotech Strategy Blog, Pieter Droppert aggregated the tweets from the BioPharm America 2011 partnering conference in Boston.

The joy of twitter is that you can follow the key messages of conference presenters remotely. It’s no substitute for being at the meeting and the networking opportunities in person, but it does allow you to capture a flavor of what everyone is thinking.  140 characters allows for a good sound bite!

Meanwhile on Pharma Strategy Blog, Sally Church has been following the ASCO Breast Cancer Symposium 2011 in San Francisco.  Icarus Consultants will be at the San Antonio Breast Cancer Symposium (SABCS) later this year.

On Pharma Strategy Blog, Sally also wrote about the European Multidisciplinary Cancer Conference in Stockholm, more commonly known as ECCO or ESMO.  The conference abstracts will be available on Monday, so we look forward to Sally’s video preview and thoughts on what’s hot at the meeting.

How to use an iPad for cancer conference coverage

September 2nd, 2011


Icarus Consultants’ social media and oncology expert, Sally Church, is also into business productivity.

iPad 2 Apple Store Picture 150x150 How to use an iPad for cancer conference coverageAt the many cancer conferences she attends each year such as ASCO, ASH, AACR and the forthcoming ESMO/ECCO/ESTRO meeting in Stockholm, an iPad is now Sally’s preferred choice of device to travel with.

How does Sally use an iPad to cover these medical conferences?

In an informative post on Pharma Strategy Blog, Sally outlines the apps that she uses and how they improve her productivity! Anyone who has seen Sally at a conference knows she covers a lot of ground – quite literally in the case of the miles that one walks at ASCO!

What is Sally’s favorite app?

HHMI Bulletin Cover May 2011 226x300 How to use an iPad for cancer conference coverageTry the Howard Hughes Medical Institute (HHMI) quarterly bulletin, that according to Sally is “a truly beautiful combination of art and science that is a pleasure to read.”

You can read more on Pharma Strategy Blog on how to use an iPad for improved productivity in science, medicine and the pharma industry.

I’ll be asking for one for Xmas this year too!

Custirsen OGX-011 a new Prostate Cancer treatment to watch

August 26th, 2011


The prostate cancer market is dynamic, with a lot of news happening. One of the many new treatments in development worth watching is custirsen (OGX-011).

Oncogenex logo Custirsen OGX 011 a new Prostate Cancer treatment to watchSally Church on Pharma Strategy Blog recently wrote about Custirsen from OncoGeneX. This drug inhibits the production of clusterin, a protein associated with the development of treatment resistance.  As Sally notes it is in essence a “chemo enhancer.”

Custirsen OGX 11 150x126 Custirsen OGX 011 a new Prostate Cancer treatment to watchPhoto: OncoGeneX

Phase 3 trials with custirsen are currently underway in castrate resistant prostate cancer patients receiving docetaxel in the first and second line setting.

The potential to improve the efficacy of docetaxel may be of commercial interest as more generic versions become available. According to IMS Health, sales of generic and branded docetaxel were approximately $1.1 billion for the year from June 2010 to June 2011.

This week Sandoz entered the market with their announcement of the FDA approval and launch of their generic version of Taxotere®.

It will be interesting to see whether use of custirsen with docetaxel increases overall survival (OS) in the phase III CRPC trials, and if it does how this compares to other recently approved CRPC treatments such as Zytiga™ (abiraterone acetate).

As Sally noted in her video blog post from the annual meeting of the American Urological Association (AUA), there is also preliminary scientific data to suggest that custirsen may improve the efficacy of androgen receptor antagonists such as MDV3100 from Medivation/Astellas.

We expect there will be new data on prostate cancer new products in development at the ESMO/ECCO European Multidisciplinary Cancer Congress in Stockholm in late September. The possibility of new treatment options is good news for prostate cancer patients. It is a market definitely worth watching.

ECCO ESMO Stockholm Cancer Conference September 2011

August 25th, 2011


Summer is almost over, and thoughts at Icarus Consultants are now turning to forthcoming medical meetings that we will be attending.

Gamla Stan swe 300x187 ECCO ESMO Stockholm Cancer Conference September 2011Photo: Max Anderson

We will be at ECCO 16 – ESMO 36 in Stockholm from September 23 – 27, 2011.

The jointly organized multidisciplinary cancer congress of the European CanCer Organisation (ECCO ) and European Society for Medical Oncology (ESMO) covers a wide range of topics from basic and translational science to surgery, radiotherapy, medical oncology, advocacy and care.

ECCO ESMO Stockholm Cancer Congress Banner ECCO ESMO Stockholm Cancer Conference September 2011You can access the preliminary programme for the meeting here.

Given the early cut-off date for submission of abstracts for the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, we expect the ECCO/ESMO Stockholm meeting will publish interesting data on a number of new products in development.

In anticipation of the meeting, Sally Church will be analyzing the abstracts (once they are available) for what’s hot and you can expect a pre-meeting video blog post.  If you missed Sally’s ASCO preview video, it is well worth watching.

Hope to see you in Stockholm.

Gamla stan 600px ECCO ESMO Stockholm Cancer Conference September 2011Photo: Stan Shebs